A recently published case report in the journal Neurocase describes an unusual and distressing psychiatric condition that ...

Natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistance and new cases over 1 year of follow up. J Clin Psychiatry 2001; 62: 46–49.

Psychosis symptoms can be just as upsetting and stressful for caregivers as they are for the person with dementia. These symptoms can make it hard for you to manage your loved one's care.

Her husband, Wes Perkins, 82, has vascular dementia and Alzheimer’s; at one point, when he required institutionalization for dementia psychosis, his care became particularly difficult.

Anti-psychotic drugs should be a last resort Most antipsychotic medications, including all that were included in the study, aren’t approved by the U.S. Food and Drug Administration to treat ...

One might be primary. For some, as [dementia] progresses, they can get them all." To find out if someone may have dementia-related psychosis, experts say, first ask yourself questions, like: ...

People with psychotic disorders such as schizophrenia are 2.5 times more likely than those without a psychotic disorder to eventually develop dementia, according to a review of evidence led by UCL ...

People with psychotic disorders such as schizophrenia are 2.5 times more likely than those without a psychotic disorder to eventually develop dementia, according to a new review.

Regarding dementia, for example, “a 1.2% increase in the population in absolute terms and compared to in other previous infections is hard to ignore,” he said.

In April 2021, the FDA rejected the Nuplazid application for dementia-related psychosis. The regulator told Acadia that the subgroups lacked evidence to show the drug’s efficacy.

First approved by the FDA in 2016 for Parkinson’s disease psychosis, Nuplazid suffered an FDA rejection in a broad dementia-related psychosis indication last April. For its second try, Acadia is ...

Neither study met its primary endpoint. Despite those failures, Acadia has continued pushing pimavanserin as a possible treatment for psychosis related to dementia and Alzheimer’s disease. The FDA ...